Cost Analysis of a Poultry Farm in Nigeria
MeganEgg – protection for commercial layers against
Salmonella enteritidis infection for consumer protection
Karen E. BurnsA, Sandra M. Kelly-AehleB, Julie A. LawrenceC
A D.V.M., M.A.M, diplomate A.C.P.V, Technical Services Veterinarian, Lohmann Animal Health International,
Inc., 1146 Airport Parkway, Gainesville, GA 30501
B Biologicals Development Director, AVANT Immunotherapeutics, Inc. dba Megan Health, Inc., 8620 Pennell
Drive, St. Louis, MO 63114
CResearch Scientist, AVANT Immunotherapeutics, Inc. dba Megan Health, Inc., 8620 Pennell Drive, St. Louis, MO
63114
In response to a rise in food safety concerns over Salmonella enteritidis, vaccination with inactivated bacterins started in the late 1980’s in the United States. These bacterins offered reduction in Salmonella excretion in feces, reduced invasion by the challenge organisms and provided passive protection through antibodies being present in the egg (3,4,5,6,9). Science progressed to the development of live attenuated vaccines derived from Salmonella typhimurium (ST) that would offer cross protection to other Salmonella species, most notably Salmonella enteritidis
(SE)(2,7). The first live vaccine of this type licensed in the United States was MeganVac 1– a double gene modified ST organism that was designed for protection of broilers through slaughter to reduce Salmonella contamination of carcasses (2). Another vaccine against SE infection has recently received USDA license. The researchers at Megan Health have developed MeganEgg, a new vaccine for pullets. This product contains the same
MeganVac 1 organism, however, MeganEgg is formulated for immunization of older birds.
Vaccine Characteristics: The vaccine is derived from a naturally occurring Salmonella typhimurium that has been genetically modified to impair two genes that are important for normal growth and metabolism. The modifications to the genes, cya and crp, result in an organism that is completely distinct from
Salmonella enteritidis infection for consumer protection
Karen E. BurnsA, Sandra M. Kelly-AehleB, Julie A. LawrenceC
A D.V.M., M.A.M, diplomate A.C.P.V, Technical Services Veterinarian, Lohmann Animal Health International,
Inc., 1146 Airport Parkway, Gainesville, GA 30501
B Biologicals Development Director, AVANT Immunotherapeutics, Inc. dba Megan Health, Inc., 8620 Pennell
Drive, St. Louis, MO 63114
CResearch Scientist, AVANT Immunotherapeutics, Inc. dba Megan Health, Inc., 8620 Pennell Drive, St. Louis, MO
63114
In response to a rise in food safety concerns over Salmonella enteritidis, vaccination with inactivated bacterins started in the late 1980’s in the United States. These bacterins offered reduction in Salmonella excretion in feces, reduced invasion by the challenge organisms and provided passive protection through antibodies being present in the egg (3,4,5,6,9). Science progressed to the development of live attenuated vaccines derived from Salmonella typhimurium (ST) that would offer cross protection to other Salmonella species, most notably Salmonella enteritidis
(SE)(2,7). The first live vaccine of this type licensed in the United States was MeganVac 1– a double gene modified ST organism that was designed for protection of broilers through slaughter to reduce Salmonella contamination of carcasses (2). Another vaccine against SE infection has recently received USDA license. The researchers at Megan Health have developed MeganEgg, a new vaccine for pullets. This product contains the same
MeganVac 1 organism, however, MeganEgg is formulated for immunization of older birds.
Vaccine Characteristics: The vaccine is derived from a naturally occurring Salmonella typhimurium that has been genetically modified to impair two genes that are important for normal growth and metabolism. The modifications to the genes, cya and crp, result in an organism that is completely distinct from